Who's that sitting in your lobby?
Watch out … it may be your regional FDA inspector, just dropping by for an unannounced inspection of your facilities.
If this happens to you — will you be ready?
Create an Inspection Readiness Gap Analysis
How to Avoid the FDA’s Top 29 483 Citations
If this fictional scenario sounds like hype to you, then listen to what just happened to the folks at device and drug maker Hospira.
Late last year — with the holiday season approaching — the FDA broadsided a major pharma company with a series of warning letters at their facilities in Colorado, North Carolina, Kansas, Illinois and Costa Rica.
Why weren't the facilities better prepared? After all, many of the problems uncovered during their inspections are common within the drug and device industries.
Don't take the chance of being next in line for an unannounced inspection.
Attend the webinar Create an Inspection Readiness Gap Analysis
on Thursday, Feb. 27, 2014.
This webinar is sure to be an eye-opener, featuring a list of the 29 top problems that repeatedly show up in 483s and warning letters.
Dr. David Lim, an accomplished former FDA official with CDRH and a pharma executive, has pulled together this 29-point hot list by combing through data from FDA inspections over the last seven years. Step-by-step, he'll reveal why —and how — the FDA focuses on all 29 of them.
It's the best possible way to begin preparing your own inspection readiness gap analysis. In 90 minutes, you'll gain an understanding of where your facility's compliance weaknesses might be, and you'll also learn:
- Why the 29 top problems continually show up in 483s — and how to best deal with these common citations
- What resources FDA investigators use to guide their inspections: IOMs, Inspection Guides, FMD and CPGM
- How the FDA manages inspection logistics: what regional office will conduct your investigation, and how your investigator will be picked
- Definitions of inspection types, categories and classifications
- What the difference is in FDA Forms 482, 483 and EIRs
- What (and how) to prepare for and respond to an FDA inspection
- Tips and best practices for communications before, during and after FDA inspections
- How to determine what the close out meeting should accomplish, and what you should do if there are lingering disagreements during the meeting
- How best to respond to a 483, and who should reply to it: in-house staff or an outside counsel/consultant?
- How to reach continuous quality and inspectional readiness, plus best practices for achieving compliance and staying compliant year round
At a time when your compliance resources are probably scarce, Dr. Lim's FDA inspection webinar is an excellent, affordable way to begin preparing your inspection readiness gap analysis. Sign up today.